REFERENCES
- Vallisa D., Bernuzzi P., Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J. Clin. Oncol. 2005; 23: 468–473, [INFOTRIEVE], [CSA]
- Seve P., Renaudier P., Sasco A. J., et al. Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France. Eur. J. Gastroenterol. Hepatol. 2004; 16: 1361–1365, [INFOTRIEVE], [CSA], [CROSSREF]
- Engels E. A., Chatterjee N., Cerhan J. R., et al. Hepatitis C virus infection and non-hodgkin lymphoma: results of the NCI-seer multi-center case-control study. Int. J. Cancer. 2004; 111: 76–80, [INFOTRIEVE], [CSA], [CROSSREF]
- Liang R., Lau G. K., Kwong Y. L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol. 1999; 17: 394–398, [INFOTRIEVE], [CSA]
- Yeo W., Zee B., Zhong S., et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer. 2004; 90: 1306–1311, [INFOTRIEVE], [CSA], [CROSSREF]
- Hoofnagle J. H., Dusheiko G. M., Schafer D. F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. 1982; 96: 447–449, [INFOTRIEVE], [CSA]
- Nagington J. Reactivation of hepatitis b after transplantation operations. Lancet. 1977; 1: 558–560, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee W. M. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733–1745, [INFOTRIEVE], [CSA], [CROSSREF]
- Papatheodoridis G. V., Dimou E., Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. 2002; 97: 1618–1628, [INFOTRIEVE], [CSA], [CROSSREF]
- Idilman R., Arat M., Soydan E., et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J. Viral Hepat. 2004; 11: 141–147, [INFOTRIEVE], [CSA], [CROSSREF]
- Tsutsumi Y., Kanamori H., Mori A., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin. Drug Saf. 2005; 4: 599–608, [INFOTRIEVE], [CSA], [CROSSREF]
- Yeo W., Chan P. K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299–307, [INFOTRIEVE], [CSA], [CROSSREF]
- Cheng A. L., Hsiung C. A., Su I. J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37: 1320–1328, [INFOTRIEVE], [CSA], [CROSSREF]
- Coiffier B. State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2005; 23: 6387–6393, [INFOTRIEVE], [CSA], [CROSSREF]
- Coiffier B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin. Adv. Hematol. Oncol. 2005; 3: 484–505, [INFOTRIEVE], [CSA]
- Rossi G., Pelizzari A., Motta M., Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 2001; 115: 58–62, [INFOTRIEVE], [CSA], [CROSSREF]
- Shibolet O., Ilan Y., Gillis S., Hubert A., Shouval D., Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100: 391–396, [INFOTRIEVE], [CSA], [CROSSREF]
- Yeo W., Chan P. K., Ho W. M., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 2004; 22: 927–934, [INFOTRIEVE], [CSA], [CROSSREF]
- Martin E., Rendon P., De Diego L., Soria M. J., Martinez M. C., Martin L. Role of lamivudine in the reactivation of hepatitis B virus infection in immunodepressed patients. Rev. Esp. Enferm. Dig. 2003; 95: 804–808, 799–803[INFOTRIEVE], [CSA]
- Stroffolini T., Andriani A., Bibas M., Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Annals of Hematology 2002; 81: 48–49, [INFOTRIEVE], [CSA], [CROSSREF]
- Vento S., Cainelli F., Longhi M. S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 2002; 3: 333–340, [INFOTRIEVE], [CSA], [CROSSREF]
- Dai M. S., Chao T. Y., Kao W. Y., Shyu R. Y., Liu T. M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 2004; 83: 769–774, [INFOTRIEVE], [CSA], [CROSSREF]
- Lim L. L., Wai C. T., Lee Y. M., et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment. Pharmacol. Ther. 2002; 16: 1939–1944, [INFOTRIEVE], [CSA], [CROSSREF]
- Enomoto M., Nishiguchi S., Seki S., Yamane T., Hino M. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am. J. Gastroenterol. 2004; 99: 1619–1620, [INFOTRIEVE], [CSA], [CROSSREF]
- Zuckerman E., Zuckerman T., Douer D., Qian D., Levine A. M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998; 83: 1224–1230, [INFOTRIEVE], [CSA], [CROSSREF]
- Johnson P. R., Yin J. A., Morris D. J., Desai M., Cinkotai K. I., McKeogh M. M. Fulminant hepatic necrosis caused by adenovirus type 5 following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 345–347, [INFOTRIEVE], [CSA]
- Sevilla J., Fernandez-Plaza S., Gonzalez-Vicent M., et al. Fatal hepatic failure secondary to acute herpes simplex virus infection. J. Pediatr. Hematol. Oncol. 2004; 26: 686–688, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee G. W., Ryu M. H., Lee J. L., et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J. Korean Med. Sci. 2003; 18: 849–854, [INFOTRIEVE], [CSA]
- Leaw S. J., Yen C. J., Huang W. T., Chen T. Y., Su W. C., Tsao C. J. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol. 2004; 83: 270–275, [INFOTRIEVE], [CSA], [CROSSREF]
- Yeo W., Ho W. M., Hui P., et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2004; 88: 209–215, [INFOTRIEVE], [CSA], [CROSSREF]
- Hoofnagle J. H., Dusheiko G. M., Schafer D. F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. 1982; 96: 447–449, [INFOTRIEVE], [CSA]
- Thung S. N., Gerber M. A., Klion F., Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch. Intern. Med. 1985; 145: 1313–1314, [INFOTRIEVE], [CSA], [CROSSREF]
- Lau J. Y., Lai C. L., Lin H. J., et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q. J. Med. 1989; 73: 911–917, [INFOTRIEVE], [CSA]
- Cherqui D., Saint-Marc Girardin M. F., Haioun C., et al. Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma. Lancet 1990; 335: 1400, [INFOTRIEVE], [CSA], [CROSSREF]
- Pinto P. C., Hu E., Bernstein-Singer M., Pinter-Brown L., Govindarajan S. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990; 65: 878–884, [INFOTRIEVE], [CSA], [CROSSREF]
- Arai N., Umeda M., Shirai T. [Successful interferon-alpha treatment of hepatitis B developing during chemotherapy of malignant lymphoma]. Rinsho Ketsueki 1992; 33: 1268–1272, [INFOTRIEVE], [CSA]
- Fan F. S., Tzeng C. H., Liu J. H., Chen P. M. Fulminant viral hepatitis B in a small lymphocytic lymphoma patient. Aust. N. Z. J. Med. 1992; 22: 512, [INFOTRIEVE], [CSA]
- Soh L. T., Ang P. T., Sng I., Chua E. J., Ong Y. W. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur. J. Cancer. 1992; 28A: 1338–1339, [INFOTRIEVE], [CSA], [CROSSREF]
- Yoshiba M., Sekiyama K., Sugata F., Okamoto H., Yamamoto K., Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig. Dis. Sci. 1992; 37: 1253–1259, [INFOTRIEVE], [CSA], [CROSSREF]
- Kumagai K., Takagi T., Sakai C., et al. [A fatal case of a hepatitis B virus carrier with fulminant hepatic failure after cytotoxic chemotherapy for malignant lymphoma]. Rinsho Ketsueki 1993; 34: 1587–1589, [INFOTRIEVE], [CSA]
- Schofield K., Morris D., Klapper P. Hepatitis after withdrawal of chemotherapy in a patient with chronic hepatitis B. J. Infect. 1993; 27: 101–102, [INFOTRIEVE], [CSA], [CROSSREF]
- Yoshiba M., Sekiyama K., Iwabuchi S., et al. Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy. Dig. Dis. Sci. 1993; 38: 1751–1755, [INFOTRIEVE], [CSA], [CROSSREF]
- Carman W. F., Korula J., Wallace L., MacPhee R., Mimms L., Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 1406–1407, [INFOTRIEVE], [CSA], [CROSSREF]
- Shimano S., Murayama K., Ogawa A., et al. [A HBV carrier with fulminant hepatitis complicated by ATL, multiple myeloma and thyroid cancer]. Rinsho Ketsueki 1995; 36: 774–779, [INFOTRIEVE], [CSA]
- Ehrmann J., Jr., Kucerova L., Jezdinska V., et al. Fulminant hepatitis caused by a hepatitis B virus infection in the patients with haematologic malignancies. Report of 5 cases. Acta Univ. Palacki Olomuc. Fac. Med. 1996; 140: 81–82, [INFOTRIEVE], [CSA]
- Haanen J. B., Bieger R., van't Wout J. W. Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection. Neth J. Med. 1996; 49: 239–243, [INFOTRIEVE], [CSA], [CROSSREF]
- Wong G. C., Tan P., Goh Y. T., Ng H. S., Chong R., Lee L. H. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann. Acad. Med. Singapore 1996; 25: 500–503, [INFOTRIEVE], [CSA]
- Sato T., Kato J., Kawanishi J., et al. Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma. J. Gastroenterol. 1997; 32: 668–671, [INFOTRIEVE], [CSA]
- Clark F. L., Drummond M. W., Chambers S., Chapman B. A., Patton W. N. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann. Oncol. 1998; 9: 385–387, [INFOTRIEVE], [CSA], [CROSSREF]
- Kondo H., Kasahara Y. Prevention of severe hepatic injury by interferon-alpha in chronic active hepatitis lacking HBeAg (mutant strain) in a patient with malignant lymphoma. Cancer Lett. 1998; 125: 171–175, [INFOTRIEVE], [CSA], [CROSSREF]
- Ahmed A., Keeffe E. B. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 249–251, [INFOTRIEVE], [CSA]
- Al-Taie O. H., Mork H., Gassel A. M., Wilhelm M., Weissbrich B., Scheurlen M. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann. Hematol. 1999; 78: 247–249, [INFOTRIEVE], [CSA]
- Senecal D., Pichon E., Dubois F., Delain M., Linassier C., Colombat P. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 1999; 24: 1243–1244, [INFOTRIEVE], [CSA], [CROSSREF]
- Sekine R., Taketazu F., Kuroki M., et al. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy. Int. J. Hematol. 2000; 71: 256–258, [INFOTRIEVE], [CSA]
- Silvestri F., Ermacora A., Sperotto A., et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br. J. Haematol. 2000; 108: 394–396, [INFOTRIEVE], [CSA], [CROSSREF]
- Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 2001; 344: 68–69, [INFOTRIEVE], [CSA], [CROSSREF]
- Hamaki T., Kami M., Kusumi E., et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am. J. Hematol. 2001; 68: 292–294, [INFOTRIEVE], [CSA], [CROSSREF]
- Kawai Y., Ikegaya S., Hata M., et al. Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature. Ann. Hematol. 2001; 80: 482–484, [INFOTRIEVE], [CSA], [CROSSREF]
- Matsuo K., Takenaka K., Shimomura H., et al. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma. Leuk. Lymphoma 2001; 41: 191–195, [INFOTRIEVE], [CSA]
- Saif M. W., Little R. F., Hamilton J. M., Allegra C. J., Wilson W. H. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann. Oncol. 2001; 12: 123–129, [INFOTRIEVE], [CSA], [CROSSREF]
- Shtalrid M., Haran M., Klepfish A., Lurie Y., Malnick S. [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration]. Harefuah 2001; 140: 1159–1162, 230, 229[INFOTRIEVE], [CSA]
- Liao C. A., Lee C. M., Wu H. C., Wang M. C., Lu S. N., Eng H. L. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 2002; 116: 166–169, [INFOTRIEVE], [CSA], [CROSSREF]
- Stroffolini T., Andriani A., Bibas M., Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann. Hematol. 2002; 81: 48–49, [INFOTRIEVE], [CSA], [CROSSREF]
- Hernandez J. A., Diloy R., Salat D., del Rio N., Martinez X., Castellvi J. M. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003; 88: ECR22, [INFOTRIEVE], [CSA]
- Larghi A., Leffler D., Frucht H., et al. Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma. J. Clin. Gastroenterol. 2003; 36: 276–280, [INFOTRIEVE], [CSA], [CROSSREF]
- Martin E., Rendon P., De Diego L., Soria M. J., Martinez M. C., Martin L. Role of lamivudine in the reactivation of hepatitis B virus infection in immunodepressed patients. Rev. Esp. Enferm. Dig. 2003; 95: 804–808, 799-803[INFOTRIEVE], [CSA]
- Ohmoto K., Tsuduki M., Yamamoto S. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus. Am. J. Gastroenterol. 2003; 98: 1215–1216, author reply 7[INFOTRIEVE], [CSA]
- Simpson N. D., Simpson P. W., Ahmed A. M., et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J. Clin. Gastroenterol. 2003; 37: 68–71, [INFOTRIEVE], [CSA], [CROSSREF]
- Westhoff T. H., Jochimsen F., Schmittel A., et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930, [INFOTRIEVE], [CSA], [CROSSREF]
- Yavuz S., Paydas S., Disel U., Sahin B., Hepatitis B. virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma. Leuk. Lymphoma 2003; 44: 1249–1250, [INFOTRIEVE], [CSA], [CROSSREF]
- Bang S. M., Kim S. S., Park S. H., et al. Acute exacerbation of chronic hepatitis B during thalidomide therapy for multiple myeloma: a case report. Korean J. Intern. Med. 2004; 19: 196–198, [INFOTRIEVE], [CSA]
- Shimizu D., Nomura K., Matsumoto Y., et al. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy. World J. Gastroenterol. 2004; 10: 2301–2302, [INFOTRIEVE], [CSA]
- Tsutsumi Y., Kawamura T., Saitoh S., et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk. Lymphoma 2004; 45: 627–629, [INFOTRIEVE], [CSA], [CROSSREF]
- Law J. K., Ho J. K., Hoskins P. J., Erb S. R., Steinbrecher U. P., Yoshida E. M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk. Lymphoma 2005; 46: 1085–1089, [INFOTRIEVE], [CSA], [CROSSREF]
- Lin P. C., Poh S. B., Lee M. Y., Hsiao L. T., Chen P. M., Chiou T. J. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int. J. Hematol. 2005; 81: 349–351, [INFOTRIEVE], [CSA], [CROSSREF]
- Soong Y. L., Lee K. M., Lui H. F., Chow W. C., Tao M., Er Loong Li, Hepatitis S. B reactivation in a patient receiving radiolabeled rituximab. Ann. Hematol. 2005; 84: 61–62, [INFOTRIEVE], [CSA], [CROSSREF]
- Zell J. A., Yoon E. J., Ignatius Ou S. H., Hoefs J. C., Chang J. C. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005; 16: 83–85, [INFOTRIEVE], [CSA], [CROSSREF]
- Sarrecchia C., Cappelli A., Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J. Infect. Chemother. 2005; 11: 189–191, [INFOTRIEVE], [CSA], [CROSSREF]
- Kempinska A., Kwak E. J., Angel J. B. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin. Infect. Dis. 2005; 41: 1277–1282, [INFOTRIEVE], [CSA], [CROSSREF]
- Novelli G., Rossi M., Ferretti G., et al. Molecular Adsorbent Recirculating System Treatment for Acute Hepatic Failure in Patients With Hepatitis B Undergoing Chemotherapy for Non-Hodgkin's Lymphoma. Transplant Proc. 2005; 37: 2560–2562, [INFOTRIEVE], [CSA], [CROSSREF]
- Imamura T., Yokosuka O., Chiba T., et al. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation. Leuk. Lymphoma 2005; 46: 915–917, [INFOTRIEVE], [CSA], [CROSSREF]
- Steinberg J. L., Yeo W., Zhong S., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J. Med. Virol. 2000; 60: 249–255, [INFOTRIEVE], [CSA], [CROSSREF]